A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

This study is testing a new cancer treatment called LM103, which uses the patient's own tumor-infiltrating immune cells (called TIL therapy), for people with advanced solid tumors such as melanoma, lung cancer, and cervical cancer. Researchers want to know if this cell therapy is safe and effective. **You may be eligible if...** - You have advanced stage III or IV melanoma, non-small cell lung cancer, cervical cancer, or another solid tumor - Standard treatments have not worked for you - You have a tumor that can be removed or biopsied to collect immune cells - Your blood counts, liver, and kidney function are within acceptable ranges - You are in good general health (ECOG 0 or 1) - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have an active or past autoimmune disease - You have severe heart, liver, or kidney problems - You have an uncontrolled infection - Your cancer has spread to the brain or the lining of the brain - You have hepatitis B, hepatitis C, or HIV - You require regular steroid treatment Talk to your doctor to see if this trial is right for you.